勃起功能障礙藥物市場規模、佔有率、成長分析（按類型、給藥途徑和地區）- 產業預測，2024-2031 年

Erectile Dysfunction Drugs Market Size, Share, Growth Analysis, By Type (Viagra, Cialis), By Route of Administration (Oral Mode of Administration, Injectable Mode of Administration), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年，勃起功能障礙藥物的全球市場規模為24億美元，從2023年的26.2億美元成長到2031年的53億美元，在預測期內（2024-2031年）預計將以複合年成長率9.2%成長。

由於幾個相互關聯的因素，勃起功能障礙藥物的全球市場正在顯著成長。肥胖、心血管疾病、糖尿病和高血壓等與文明病的流行，以及久坐生活方式的增加，導致對這些藥物的需求增加。此外，隨著患者對勃起功能障礙認知的提高，老年人口的不斷成長也增加了對有效治療方案的需求。新興市場的政府措施和公共衛生宣傳活動正在進一步支持市場擴張。替代學名藥的存在以及相關的生活方式壓力也正在增加市場活力。此外，越來越多的男性出現勃起功能障礙，以及關鍵藥物專利的到期，都證明了有利的市場條件。對研發的投資以及專注於創新治療的臨床試驗正在創造強勁的成長機會。然而，市場面臨著患者依從性差、假藥盛行以及可能阻礙進展的潛在副作用等挑戰。隨著市場的發展，相關人員必須解決這些障礙，同時利用成長動力來有效駕馭複雜的勃起功能障礙藥物市場。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）
Merck & Co., Inc.（US）
Bausch Health Companies Inc.（Canada）
Hims, Inc.（US）
Sildenafil Therapeutics LLC（US）
Eli Lilly and Company（US）
MediSprout（US）
NantKwest, Inc.（US）
Cipla Limited（India）
Apexigen, Inc.（US）
NantWorks LLC（US）
Sorrento Therapeutics, Inc.（US）
Tetra Bio-Pharma Inc.（Canada）

簡介目錄

Product Code: SQMIG35I2259

Global Erectile Dysfunction Drugs Market size was valued at USD 2.4 billion in 2022 and is poised to grow from USD 2.62 billion in 2023 to USD 5.3 billion by 2031, growing at a CAGR of 9.20% during the forecast period (2024-2031).

The global market for erectile dysfunction drugs is witnessing significant growth driven by several interconnected factors. The rise in sedentary lifestyles, alongside the prevalence of lifestyle-related conditions such as obesity, cardiovascular diseases, diabetes, and hypertension, is leading to a higher demand for these medications. Additionally, the growing geriatric population is amplifying the need for effective treatment options, supported by increased patient awareness around erectile dysfunction. Government initiatives and public health campaigns in developing regions are further propelling market expansion. The presence of generic drug alternatives and associated lifestyle stresses are enhancing market dynamics as well. Furthermore, an increasing number of men experiencing erectile dysfunction, coupled with the expiration of patents for major drugs, is proving advantageous for the market landscape. Investment in research and development, along with clinical trials focusing on innovative treatments, is creating robust growth opportunities. However, the market faces challenges such as poor patient adherence, the prevalence of counterfeit medications, and potential adverse effects that may impede progress. As the market evolves, addressing these hurdles while capitalizing on growth drivers will be crucial for stakeholders to navigate the complexities of the erectile dysfunction drug market effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Drugs Market Segmental Analysis

Global Erectile Dysfunction Drugs Market is segmented by Type, Route of Administration, and region. Based on Type, the market is segmented into Viagra (sildenafil citrate), Cialis (Tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), and Other Drugs. Based on Route of Administration, the market is segmented into Oral Mode of Administration, Injectable Mode of Administration, and Other Modes of Administration. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Erectile Dysfunction Drugs Market

The escalating prevalence of erectile dysfunction (ED) worldwide significantly propels the Global Erectile Dysfunction Drugs market, driven by a confluence of factors including sedentary lifestyles, obesity, and age-related changes. Chronic health conditions such as diabetes and cardiovascular diseases further exacerbate this issue, leading to a higher demand for effective treatment options. As societal awareness surrounding men's health increases and stigma surrounding ED diminishes, more individuals are seeking medical interventions. This trend is further supported by ongoing innovations in pharmaceutical therapies, bolstering the market's growth as a rising number of patients turn to prescribed medications and over-the-counter solutions to enhance their sexual health and overall quality of life.

Restraints in the Global Erectile Dysfunction Drugs Market

One significant market restraint for the global erectile dysfunction drugs market is the rigorous regulatory landscape governing drug development and approval. The process involves extensive clinical trials and stringent post-marketing surveillance requirements, which are both time-consuming and costly for manufacturers. These regulatory hurdles can delay product launches and increase the overall investment needed for bringing new drugs to market. Consequently, the complexity and duration of the approval process may deter potential entrants and limit innovation within the sector, ultimately constraining market growth and reducing the availability of novel treatment options for consumers seeking effective erectile dysfunction solutions.

Market Trends of the Global Erectile Dysfunction Drugs Market

The Global Erectile Dysfunction Drugs market is experiencing a notable shift towards non-oral administration routes, driven by an evolving consumer preference for treatment options that enhance convenience and immediacy. As traditional oral medications, particularly PDE5 inhibitors, continue to dominate the landscape, there is a marked rise in interest for alternative methods such as topical creams, injections, and transdermal patches. These innovative delivery systems provide localized treatment, potentially reducing systemic side effects and improving efficacy. This trend reflects a broader movement towards personalized medicine, catering to diverse patient needs and preferences, thereby fostering growth opportunities within the market.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Case study Analysis
PESTEL Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition

Erectile Dysfunction Drugs Market by Product

Market Overview
Viagra (sildenafil citrate)
Cialis (Tadalafil)
Levitra/Staxyn (vardenafil)
Stendra/Spedra (avanafil)
Zydena (udenafil)
Other Drugs

Erectile Dysfunction Drugs Market by Route of Administration

Market Overview
Oral Mode of Administration
Injectable Mode of Administration
Other Modes of Administration

Erectile Dysfunction Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hims, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sildenafil Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediSprout (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apexigen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantWorks LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetra Bio-Pharma Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments